Skip to content

Cognitive Rehabilitation for Opioid Abuse-related Cognitive Impairment

Cognitive Rehabilitation for Opioid Abuse-related Cognitive Impairment

Status
Suspended
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04404348
Enrollment
50
Registered
2020-05-27
Start date
2020-03-06
Completion date
2020-12-31
Last updated
2020-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Substance-Related Disorders

Brief summary

Research has consistently found that cognitive impairment is common in persons with a history of substance abuse. The most commonly identified impairments across all substances are in attentional and working memory functioning and executive functioning; opioid-specific research finds that memory is an additional area of common impairment. Initial research in applying cognitive rehabilitation methods to substance abuse have shown it to be helpful overall. To develop a cognitive rehabilitation intervention that is effective for opioid abuse, this study will adapt a cognitive training program that has been shown to be effective in other patient groups. Patients in a residential opioid-abuse treatment program will undergo a cognitive evaluation and then be assigned to receive the 4-week cognitive intervention or the 4-week placebo control arm. It is expected that the intervention group will show greater gains on the cognitive post test and will have higher rated treatment adherence and opioid treatment program completion rates.

Interventions

BEHAVIORALCognitive Training

Exercises used will be: Mind Bender, Divided Attention, Freeze Frame, Mixed Signals, Target Tracker, To Do List.

BEHAVIORALPlacebo Control

Games are drawn from the set of research control games provided by Posit Science-Brain HQ.

Sponsors

Oklahoma State University Center for Health Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
No

Inclusion criteria

* Has completed the detoxification process * Has completed at least 8 years of formal education * Speaks and reads English fluently * Is beginning residential inpatient treatment for opioid abuse (note: may be receiving treatment for polysubstance abuse but opioid must be one of their regular drugs of abuse)

Exclusion criteria

* Unable to self-consent (has a proxy for medical decision-making, legal guardian, or been otherwise determined unable to give consent) * Past diagnosis or suspected current diagnosis of a neurodevelopmental disorder (e.g., autism, learning disability), attention-deficit disorder, or neurocognitive disorder (e.g., dementia) * History of major head trauma (defined as loss of consciousness for 30 minutes or longer) or brain surgery. (Note: History of concussion, including brief loss of consciousness, is okay)

Design outcomes

Primary

MeasureTime frameDescription
Mean Cognitive Change from Baseline to EndpointPost-intervention at week 4Change in overall cognitive summary score from pretest to posttest on NIH Toolbox.
Substance Abuse Program Completion RateUntil treatment program discharge, usually 30-45 daysCompletion rate of recommended treatment program length, quantified as percentage completed

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026